Serum urate home monitoring for gout using a Point-of-Care Testing Meter and nurse-led treat-to-target approach: A feasibility study - Home Monitoring Gout

Sint Maartenskliniek0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a patient subject must
•meet all of the following criteria:
•Have a clinical diagnosis of gout
•Are older than 16 years of age
•Not at sUA target of 0.36 mmol/L (or 0.30 for tophaceous gout, chronic
•arthropathy and frequent attacks), based on lab results not older than 6 weeks.
•Starting ULT (allopurinol, benzbromarone, febuxostat, probenecid or
•pegloticase) or using ULT but not at sUA target
•Able and willing to sign informed consent
•Possession of a digital device (e.g. smartphone, laptop, tablet), email
•address and in-ternet connection
•Willing to use a POCT at home
•Sufficient understanding of the Dutch language
•Stakeholders:
•In order to be eligible for the stakeholder interviews, a stakeholder must have
•been involved in involved in carrying out, or managing the current study.

•Patients who have contra indications for using urate-lowering therapry (ULT)
•and not being able to measure sUA at home. Patients with mild kidney disease
•(CKD-EPI between 0.45 and 0.90 ml/min/1.73m2) can be included but patients with
•severe kidney disease (CKD-EPI < 0.45 ml/min/1.73m2) or severe liver function
•problems (i.e. ALAT 3 times higher than normal range, liver cirrhosis etc.)
•will be excluded.

发起方